These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24395025)

  • 21. Safety and Efficacy of Simultaneous Inoculations of Pneumococcal and Influenza Vaccines in Patients with Coronary Artery Disease.
    Shimada K; Morinaga H; Kiyanagi T; Miyazaki T; Nishitani-Yokoyama M; Okai I; Tamura H; Konishi H; Kurata T; Miyauchi K; Daida H
    J Atheroscler Thromb; 2021 Aug; 28(8):826-834. PubMed ID: 33055462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study.
    Simpson CR; Lone NI; Kavanagh K; Englishby T; Robertson C; McMenamin J; Wissman BV; Vasileiou E; Butler CC; Ritchie LD; Gunson R; Schwarze J; Sheikh A
    Health Technol Assess; 2020 Dec; 24(67):1-66. PubMed ID: 33256892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective cohort study comparing the reactogenicity of trivalent influenza vaccine in pregnant and non-pregnant women.
    Regan AK; Tracey L; Blyth CC; Mak DB; Richmond PC; Shellam G; Talbot C; Effler PV
    BMC Pregnancy Childbirth; 2015 Mar; 15():61. PubMed ID: 25880741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of a text messaging intervention on influenza vaccination in an urban, low-income pediatric and adolescent population: a randomized controlled trial.
    Stockwell MS; Kharbanda EO; Martinez RA; Vargas CY; Vawdrey DK; Camargo S
    JAMA; 2012 Apr; 307(16):1702-8. PubMed ID: 22535855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months.
    Carmona Martinez A; Salamanca de la Cueva I; Boutet P; Vanden Abeele C; Smolenov I; Devaster JM
    Hum Vaccin Immunother; 2014; 10(7):1959-68. PubMed ID: 25424805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults.
    Leeb A; Carcione D; Richmond PC; Jacoby P; Effler PV
    Vaccine; 2011 Oct; 29(45):7920-4. PubMed ID: 21864621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.
    Rosenberg M; Sparks R; McMahon A; Iskander J; Campbell JD; Edwards KM
    Vaccine; 2009 Jul; 27(32):4278-83. PubMed ID: 19450636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries.
    Thompson A; Gurtman A; Patterson S; Juergens C; Laudat F; Emini EA; Gruber WC; Scott DA
    Vaccine; 2013 Oct; 31(45):5289-95. PubMed ID: 23973321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
    Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
    de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
    Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1).
    Chan TC; Hung IF; Luk JK; Shea YF; Chan FH; Woo PC; Chu LW
    J Am Med Dir Assoc; 2012 Oct; 13(8):698-703. PubMed ID: 22722051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink.
    Glanz JM; Newcomer SR; Hambidge SJ; Daley MF; Narwaney KJ; Xu S; Lee GM; Baggs J; Klein NP; Nordin JD; Naleway AL; Belongia EA; Weintraub ES
    Arch Pediatr Adolesc Med; 2011 Aug; 165(8):749-55. PubMed ID: 21810637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
    JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged ≥6 months to <36 months: a comparison of published and unpublished studies.
    Kaczmarek MC; Duong UT; Ware RS; Lambert SB; Kelly HA
    Vaccine; 2013 Nov; 31(46):5359-65. PubMed ID: 24055353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.
    Lara C; De Graeve D; Franco F
    Value Health Reg Issues; 2018 Dec; 17():21-31. PubMed ID: 29626706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.
    Gaglani M; Spencer S; Ball S; Song J; Naleway A; Henkle E; Bozeman S; Reynolds S; Sessions W; Hancock K; Thompson M
    J Infect Dis; 2014 Jun; 209(11):1705-14. PubMed ID: 24363436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oil-in-water emulsion adjuvant with influenza vaccine in young children.
    Vesikari T; Knuf M; Wutzler P; Karvonen A; Kieninger-Baum D; Schmitt HJ; Baehner F; Borkowski A; Tsai TF; Clemens R
    N Engl J Med; 2011 Oct; 365(15):1406-16. PubMed ID: 21995388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.